MTOR and infection: In the phase 2b and phase 3 randomized trials of the oral mTOR inhibitor RTB101 (formerly known as BEZ235) conducted in adults aged 65 years and older, Mannick et al. found that RTB101 enhances antiviral immunity through the interferon (IFN)-mediated antiviral pathway, thereby improving immunosenescence and alleviating infection-driven inflammaging (Mannick et al., 2021).